Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

INTRODUCTION: The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) targets human epidermal growth factor receptor 2 (HER2) and has been evaluated in patients with HER2-positive unresectable/metastatic breast cancer in the phase II DESTINY-Breast01 trial (NCT03248492; DS8201-A-U201) and the ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Rugo, H.S., Bianchini, G., Cortes, J., Henning, J.-W., Untch, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375150/
https://www.ncbi.nlm.nih.gov/pubmed/35964548
http://dx.doi.org/10.1016/j.esmoop.2022.100553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375150/
https://www.ncbi.nlm.nih.gov/pubmed/35964548
http://dx.doi.org/10.1016/j.esmoop.2022.100553

Ejemplares similares